KFAS
SLS icon

Keating Financial Advisory Services’s SELLAS Life Sciences SLS Stock Holding History

Keating Financial Advisory Services’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$177 Buy
12
+5
+71% +$35 ﹤0.01% 2435
2026
Q1 		$30 Buy
+7
New +$31 ﹤0.01% 2480

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Keating Financial Advisory Services's SLS Position: Q2 2026 in Review

Keating Financial Advisory Services increased its SELLAS Life Sciences (SLS) stake by 71% in Q2 2026, buying an estimated $35 and bringing the position to 12 shares worth $177. The position accounts for ﹤0.01% of the portfolio, ranked #2435.

Keating Financial Advisory Services first reported a position in SLS in Q1 2026 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Keating Financial Advisory Services held 12 shares of SELLAS Life Sciences worth $177 as of Q2 2026.
  • Keating Financial Advisory Services bought 5 SELLAS Life Sciences shares in Q2 2026, an estimated $35.
  • SELLAS Life Sciences made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2435 holding.
  • Keating Financial Advisory Services first reported a position in SELLAS Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.